Altria vs. Philip Morris: Which Stock Smokes Out Better Returns?

Altria (MO) reported an 8.3% rise in Q2 2025 adjusted EPS to $1.44, bolstered by a 26.5% surge in 'on!' oral tobacco shipments and resilient smokeable product performance, despite a 10.2% decline in domestic cigarette volumes. Meanwhile, Philip Morris International (PM) lifted its 2025 adjusted EPS guidance to $7.43-$7.56, driven by smoke-free products accounting for 41% of Q2 revenue and over $500 million in H1 cost efficiencies. The analysis concludes that while Altria appeals to income investors, PM is the stronger long-term investment due to its global scale and leadership in smoke-free innovation, positioning it better for the evolving tobacco market.

Analysis

Both Altria (MO) and Philip Morris (PM) are navigating the structural decline of combustible tobacco by pivoting to smoke-free alternatives, though their strategies and growth trajectories diverge significantly. Altria reported resilient Q2 2025 results, with adjusted EPS rising 8.3% to $1.44 and full-year guidance lifted to 3-5% growth. This performance is driven by strong pricing in its smokeable segment, where Marlboro's share expanded to 59.5%, and substantial momentum in its oral tobacco division, where 'on!' pouch shipments grew 26.5%, boosting segment margins to 68.7%. However, this is set against a stark 10.2% decline in domestic cigarette shipment volumes, a significant headwind. In contrast, Philip Morris demonstrates a more aggressive and successful transformation, raising its 2025 EPS growth guidance to 13-15%. Smoke-free products now account for 41% of PM's total net revenue, and the company is on track to achieve $2 billion in cost efficiencies by 2026. While PM also faces declining cigarette volumes (down 1.5% in Q2), its global scale and leadership in heated tobacco provide a stronger foundation for long-term growth, justifying its premium forward P/E of 21.25 compared to Altria's 12.29.

Key Decisions for Investors

• Growth-oriented investors should favor Philip Morris, as its superior EPS growth guidance of 13-15% and successful pivot to smoke-free products, now 41% of revenue, indicate a stronger long-term expansion profile despite its premium valuation.
• Income and value-focused investors may find Altria's lower forward P/E of 12.29 attractive, supported by its resilient profitability, strong pricing power, and the rapid 26.5% shipment growth in its 'on!' oral tobacco brand, which partially mitigates declining cigarette volumes.
• Investors in either company must closely monitor the rate of cigarette volume decline, a key industry headwind, noting Altria's steep 10.2% Q2 drop and Philip Morris's forecast for an accelerating 3-4% decline in the second half of the year.
• Despite PM's stronger fundamental outlook, Altria's recent stock outperformance of 15.2% over the past month suggests the market is rewarding its near-term execution and success in the high-margin oral tobacco segment.